CHARLES KRYSL: Open Payments
NPI 1538132899 · GERING, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 21 payments from 9 companies in 2025. Trend: 2023 $27 · 2024 $200 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $201 |
| Stryker Corporation | 1 | $143 |
| Novo Nordisk Inc | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Lilly USA, LLC | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 3 | $32 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences Corporation | 1 | $14 |
Products named: QULIPTA, FLOWTRIEVER, CAPLYTA, VRAYLAR, Ozempic, MOUNJARO, VOQUEZNA, BREZTRI.
Industry payments across NE — which companies pay providers there.
